Back to CVE records
Medium 6.5Published Sep 13, 2026

CVE-2026-90513simalexan api-lambda-send-email-ses API Gateway Endpoint template.yml SES.sendEmail missing authentication

Updated under an hour ago ()

Does this affect you?

It affects simalexan api-lambda-send-email-ses. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

A flaw has been found in simalexan api-lambda-send-email-ses up to bda6869aa81371d1e872242e74fe7d953edb818d. This issue affects the function SES.sendEmail of the file template.yml of the component API Gateway Endpoint. This manipulation of the argument toEmails/ccEmails/replyToEmails/subject/message causes missing authentication. It is possible to initiate the attack remotely. This product is using a rolling release to provide continious delivery. Therefore, no version details for affected nor updated releases are available. The project was informed of the problem early through an issue report but has not responded yet.

CVSS
6.5 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L/E:X/RL:X/RC:R
Weakness (CWE)
CWE-306, CWE-287
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulDB
NVD analysis
Deferred
Record last updated
Sep 14, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
simalexan api-lambda-send-email-ses
simalexan:api-lambda-send-email-ses
bda6869aa81371d1e872242e74fe7d953edb818d
CNA record

References

  • vdb-entry, technical-description
  • signature, permissions-required
  • third-party-advisory
  • third-party-advisory
  • issue-tracking
  • product

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.